Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 22, 2023LeukemiaOpen Access

Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results

View Full Paper
Ask AI
Bookmark
Share

Authors

MMMichael J. MauroMemorial Sloan Kettering Cancer CenterTHTimothy P. HughesSouth Australia PathologyDKDong‐Wook KimUniversity Health Network

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Mauro et al. (2023) studied this question.

synapsesocial.com/papers/6a7073dae5469ee92be12fc5https://doi.org/10.1038/s41375-023-01860-w
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs2021 · 347 citations
  2. 2Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors2013 · 65 citations
  3. 3Long‐term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib2016 · 115 citations
  4. 4Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: An Analysis of the FDA Adverse Event Reporting System Database (FAERS)2020 · 145 citations
  5. 5Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV2013 · 302 citations